<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00768508</url>
  </required_header>
  <id_info>
    <org_study_id>12790</org_study_id>
    <secondary_id>R01AA012964</secondary_id>
    <nct_id>NCT00768508</nct_id>
  </id_info>
  <brief_title>Combined Pharmacotherapies for Alcoholism</brief_title>
  <official_title>Combined Pharmacotherapies for Alcoholism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bankole Johnson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study would like to test whether the combination of ondansetron and naltrexone will be
      superior to either medication alone or placebo in the treatment of alcohol dependence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to conduct a 13 week randomized, controlled clinical trial to evaluate the safety
      and efficacy of ondansetron and naltrexone alone and in combination.Eligible subjects will be
      randomized to placebo, ondansetron, naltrexone, or ondansetron + naltrexone treatments. All
      subjects will receive a weekly CBT (Cognitive Behavioral Therapy)sessions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-report measures of alcohol-related problems and consumption, Objective measures of alcohol consumption</measure>
    <time_frame>Throughout the study</time_frame>
    <description>Drinks per drinking day, Drinks per day, Percent Days Abstinent, BAC, CDT, GGT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication compliance, alcohol craving, social functioning, quality of life, alcohol withdrawal, attendance at psychosocial services, pre-morbid risk factors</measure>
    <time_frame>Throughout the study</time_frame>
    <description>Pill Count, SFQ, AASE, ADBS, OCDS, CIWA-Ar, CGI, TCI, MAC, AOQ, FHAM</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>Ondansetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naltrexone 50 mg/day + Cognitive Behavioral Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ondansetron + Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ondansetron 4 ug/kg b.i.d. + Naltrexone 50 mg/day + Cognitive Behavioral Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + Cognitive Behavioral Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy</intervention_name>
    <description>Ondansetron 4 ug/kg b.i.d.for 12 weeks</description>
    <arm_group_label>Ondansetron</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone 50 mg/day + Cognitive Behavioral Therapy</intervention_name>
    <description>Naltrexone 50 mg/day for 12 weeks</description>
    <arm_group_label>Naltrexone</arm_group_label>
    <other_name>Revia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy</intervention_name>
    <description>Combination of ondansetron 4 ug/kg b.i.d. and naltrexone 50 mg/day for 12 weeks</description>
    <arm_group_label>Ondansetron + Naltrexone</arm_group_label>
    <other_name>Zofran and Revia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo + Cognitive Behavioral Therapy</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females who have given written informed consent.

          -  Ages 18 years and above and must weigh at least 40 kg and no more than 140 kg.

          -  Good physical health as determined by a complete physical examination, an EKG within
             normal limits, and laboratory screening tests within acceptable parameters (see
             exclusion criteria).

          -  Current DSM-IV diagnosis of alcohol dependence

          -  AUDIT score of equal or more than 8.

          -  Currently drinking

          -  Provide evidence of stable residence in the last month prior to enrollment in the
             study, and have no plans to move in the next three months.

          -  The pregnancy test for females at intake must be negative. Additionally, women of
             childbearing potential must be using an acceptable form of contraception. These
             include: oral contraceptives, hormonal (levonorgestrel) or surgical implants, or
             barrier plus spermicide.

          -  Literate in English and able to read, understand, and complete the ratings scales and
             questionnaires accurately, follow instructions, and make use of the behavioral
             treatments.

          -  Answer an advertisement in the newspaper/radio/television, or be referred from a
             health care professional and express a wish to stop drinking.

          -  Willingness to participate in behavioral treatments for alcoholism.

        Exclusion Criteria:

          -  Any current axis I DSM IV psychiatric disorder other than alcohol or nicotine
             dependence

          -  Elevation of liver enzymes - (SGOT), serum glutamic pyruvic transaminase (SGPT), blood
             urea nitrogen (BUN), or lactate dehydrogenase (LDH) greater than four times the normal
             range, or clinically significant elevated direct bilirubin as deemed by the principal
             investigator.

          -  Severe alcohol withdrawal symptoms which in the physicians opinion requires inpatient
             treatment.

          -  Serious medical co-morbidity requiring medical intervention or close supervision, or
             any condition which can interfere with the receipt of ondansetron.

          -  Severe or life-threatening adverse reactions to medications in the past or during this
             clinical trial.

          -  Female patients who are pregnant, lactating, or not adhering to an acceptable form of
             contraception at any time during the study.

          -  Received inpatient or outpatient treatment for alcohol dependence within the last 30
             days (support groups such as AA are not exclusionary).

          -  Compelled to participate in an alcohol treatment program to maintain their liberty.

          -  Members of the same household.

          -  Concurrent treatment with any medications having a potential effect on alcohol
             consumption and related behaviors, or mood. These include: opiate antagonist (e.g.
             naltrexone), glutamate antagonists (e.g., acamprosate), serotonin re-uptake inhibitors
             (e.g. fluoxetine), serotonin antagonists (e.g. ritanserin or buspirone), other
             antidepressants (e.g. tricylic antidepressants or monoamine oxidase inhibitors),
             dopamine antagonists (e.g. haloperidol), calcium channel antagonists (e.g.
             isradipine), or compounds with actions similar to disulfiram (antabuse) or nicotine.

          -  Before double-blind randomization, urine must be free of opiates, cocaine,
             amphetamines, barbiturates, benzodiazepines, prescription and non-prescription drugs.

          -  Pyrexia of unknown origin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bankole Johnson, DSc,MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UVA CARE</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UVA CARE Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2008</study_first_submitted>
  <study_first_submitted_qc>October 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2008</study_first_posted>
  <last_update_submitted>March 14, 2013</last_update_submitted>
  <last_update_submitted_qc>March 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Bankole Johnson</investigator_full_name>
    <investigator_title>Chair of Psychiatry and NB Sciences</investigator_title>
  </responsible_party>
  <keyword>Alcohol</keyword>
  <keyword>Alcohol Dependence</keyword>
  <keyword>Alcoholism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

